NFA
AGRX

Nationwide Fund Advisors’s Agile Therapeutics AGRX Stock Holding History

Nationwide Fund Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4
Closed -$26K – 3287
2017
Q1 		$26K Hold
4
– – ﹤0.01% 3065
2016
Q4 		$45K Hold
4
– – ﹤0.01% 3020
2016
Q3 		$56K Hold
4
– – ﹤0.01% 3034
2016
Q2 		$61K Buy
4
+1
+33% +$13.7K ﹤0.01% 3049
2016
Q1 		$57K Hold
3
– – ﹤0.01% 2964
2015
Q4 		$64K Hold
3
– – ﹤0.01% 2953
2015
Q3 		$44K Hold
3
– – ﹤0.01% 3039
2015
Q2 		$56K Buy
+3
New +$64K ﹤0.01% 3096

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Nationwide Fund Advisors's AGRX Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Agile Therapeutics (AGRX) in Q2 2017, closing a stake of 4 shares — an estimated $26K sold.

Nationwide Fund Advisors first reported a position in AGRX in Q2 2015 and held it in 8 quarters. The position peaked at $64K in Q4 2015. 41 funds tracked by Wall St. Rank hold AGRX as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining Agile Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 4 Agile Therapeutics shares in Q2 2017, an estimated $26K.
  • Nationwide Fund Advisors first reported a position in Agile Therapeutics in Q2 2015 and held it in 8 quarters.
  • Nationwide Fund Advisors's Agile Therapeutics position peaked at $64K in Q4 2015.
  • 41 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.